research Rutin Stabilises β-Catenin Through GSK3β Inhibition to Promote Hair Follicle Regeneration.
Rutin may help regrow hair by stabilizing β-catenin and blocking GSK3β.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Corn silk extract improves benign prostatic hyperplasia in experimental rat model
Corn silk extract helps reduce prostate enlargement symptoms.
research Rizatriptan benzoate-loaded dissolving microneedle patch for management of acute migraine therapy
Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Serenoa Repens for the Treatment of Capillary Disorders
Serenoa repens, a natural compound, can increase hair count and help repair capillaries, making it a promising treatment for hair loss.
research ACE2 Inhibits Dermal Regeneration Through Ang II in Tissue Expansion
Inhibiting ACE2 improves skin regeneration during tissue expansion.
research The Experimental Study on the Effect of Herbal Exrtacts on Hair Growth and Acnes
Rubus coreanum may help hair growth but not through the tested mechanisms, and none of the herbal extracts help with acne.
research Fructus Psoraleae Treating in Androgenetic Alopecia Through 5-Α Reductase Inhibition and Nrf2-Keap1 Pathway
Fructus Psoraleae may help treat hair loss by inhibiting 5-α reductase and affecting the Nrf2-Keap1 pathway.
research Co-delivering Retinol and Niacinamide via Liposomes: Enhanced Stability, Efficient Skin Permeation, and Improved Anti-Aging/Skin-Brightening Efficacy
The new delivery system makes retinol and niacinamide more stable and effective for anti-aging and skin-brightening.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.